Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|HER2/Neu Positive|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIC Breast Cancer AJCC v6|Stage IV Breast Cancer AJCC v6 and v7
Interventions: BIOLOGICAL: Bevacizumab|DRUG: Ixabepilone|OTHER: Laboratory Biomarker Analysis|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|OTHER: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)